Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31411045 | 1.00 | GPR119 (0.51) | GPR119PIK3CDTBK1CHEK2NAMPT | |
| SCHEMBL20120441 | 1.00 | GPR119 (0.51) | GPR119PIK3CDTBK1CHEK2NAMPT | |
| SCHEMBL20120443 | 1.00 | GPR119 (0.51) | GPR119PIK3CDTBK1CHEK2NAMPT | |
| SCHEMBL20213828 | 0.87 | MAPT (0.42) | GPR119 | |
| SCHEMBL20128893 | 0.86 | TBK1 (0.44) | GPR119PIK3CDTBK1NAMPT | |
| SCHEMBL20233560 | 0.85 | TDO2 (0.46) | — | |
| SCHEMBL20128900 | 0.85 | TBK1 (0.43) | GPR119PIK3CDTBK1 | |
| SCHEMBL20120729 | 0.85 | TBK1 (0.43) | GPR119PIK3CDTBK1 | |
| SCHEMBL29547748 | 0.85 | TBK1 (0.43) | GPR119PIK3CDTBK1 | |
| SCHEMBL20120731 | 0.85 | TBK1 (0.43) | GPR119PIK3CDTBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20230086457-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-23 | — | — | US | disclosed |
| EP-3999182-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230086457-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | GPR119 3741/4885PIK3CD 2652/4885TBK1 406/4885 |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | GPR119 3766/4885PIK3CD 2740/4885TBK1 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.